Cohort C

BIOLOGICAL3 trials

Sponsors

Ionis Pharmaceuticals, Inc., Institut du Cancer de Montpellier - Val d'Aurelle, Uniquity One (UNI)

Conditions

Breast CancerChronic anemia due to ineffective erythropoiesis (IE) in subjects with ß thalassemia thalassemiaHealthy

Phase 1

A Study to Investigate Efficacy and Safety of NSI-8226 in Healthy Participants

CompletedNCT06640920

Uniquity One (UNI)Healthy

Start: 2024-04-29End: 2024-10-29Updated: 2025-08-12

Phase 2

A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ISIS 702843 Administered Subcutaneously to Patients with Non-Transfusion Dependent ß-Thalassemia Intermedia

Active, not recruitingLBCTR2020071296

Ionis Pharmaceuticals, Inc.Chronic anemia due to ineffective erythropoiesis (IE) in subjects with ß thalassemia thalassemia

Start: 2020-02-17Target: 36Updated: 2026-02-02

Unknown Phase

Personalization of Breast Radiotherapy According to Loco-regional Recurrence Risk and Toxicity Probability

RecruitingNCT06382818

Institut du Cancer de Montpellier - Val d'AurelleBreast Cancer

Start: 2025-03-06End: 2038-03-06Target: 854Updated: 2026-03-12